Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post‐<scp>BCR</scp>inhibitor setting: a<scp>UK</scp>wide analysis
Toby A. Eyre(Oxford University Hospitals NHS Trust), Nimish Shah(National Health Service), Renata Walewska(Dorset HealthCare University NHS Foundation Trust), George Follows(Addenbrooke's Hospital), Rosalynd Johnston(Royal Sussex County Hospital), Amy A. Kirkwood(Cancer Research UK), Adrian Bloor(The Christie NHS Foundation Trust), Harriet S. Walter(Leicester Royal Infirmary), Matt Cross(Royal Marsden Hospital), Arvind Arumainathan(Clatterbridge Cancer Centre NHS Foundation Trust), Piers Patten, Kim Orchard(University of Namur), Andy Dann(Ipswich Hospital), Richard Chasty(University Hospitals of North Midlands NHS Trust), Shankara Paneesha(University of Leeds), Anna Schuh(University of Oxford), Francesco Forconi(University of Leeds), Christopher P. Fox(University of Nottingham), Satyen H. Gohil(Broad Institute), Tal Munir(St James's University Hospital), Angus Broom(Western General Hospital), Helen Marr(Freeman Hospital), Alistair Hart(Queen Elizabeth University Hospital)
Cited by 79
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523